Trial Runners

Executive Summary

Trial Runners is a specialized Contract Research Organization (CRO) focused exclusively on ophthalmology clinical trials. Founded in 2018 in San Francisco, the company differentiates itself from larger, generalist CROs by offering a lean, expert-led model with direct executive oversight. This approach aims to accelerate trial timelines and improve quality for biotech and medtech sponsors developing ophthalmic therapies. By concentrating solely on ophthalmology, Trial Runners can leverage deep domain expertise and established relationships with key opinion leaders and clinical sites, potentially reducing patient recruitment challenges common in eye disease trials. The company operates in a growing niche, as the global ophthalmic drugs market is projected to expand due to aging populations and rising prevalence of conditions like age-related macular degeneration, diabetic retinopathy, and glaucoma. As a private, bootstrapped firm, Trial Runners may be well-positioned to capture market share from larger CROs that often lack specialization. However, its size also presents risks, including limited capacity and dependence on a few key clients. Near-term catalysts could include wins from new biotech sponsors, expansion of service offerings into medical device trials, or strategic partnerships with pharmaceutical companies. With a focused strategy and experienced team, Trial Runners has the potential to become a go-to CRO in ophthalmology, though scaling operations remains a key challenge.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a major contract with a mid-to-large pharma sponsor for a late-stage ophthalmology trial40% success
• Q4 2026Expansion into ophthalmic medical device clinical trials, broadening the addressable market50% success
• TBDPartnership or joint venture with a retinal imaging or diagnostic company to offer integrated trial services30% success